has been difficult in clinical trial settings, and many drugs have failed because of inadequate patient selec-1
Figure 1. Chemical Structures of GM, 17AAG, RD, and the Designed PU Class of Hsp90 Inhibitors and Its Representative, PU24FCl
cannot be fully explored because of limitations of the cific binding to the N-terminal pocket of Hsp90 [24] . We mentally distilled these requirements and designed the existent inhibitors. To address that, we have developed a family of novel small molecules that potently and selec-molecular class (PU class) illustrated in Figure 1 [25] . Rational changes in the variables X 1 , X 2 , and X 3 led to tively inhibit Hsp90. We show here that one of these agents, PU24FCl, is highly specific for tumor Hsp90 and the development of PU24FCl (Figure 1) [26]. PU24FCl is a representative of this class and is by no means the retains similar potency against a broad range of tumors in concordance with its inhibitory activity of tumor most potent. In its design, empirical rules for solubility and cell permeability [27] and bioavailability [28] were Hsp90. We also show that the agent manifests its anticancer activities via degradation of Hsp90 client proteins additionally considered. involved in tumor growth and survival, tumor-specific transformation, inhibition of cancer cell growth, delay PU24FCl Is Highly Specific for Tumor Hsp90 of cell cycle progression, and induction of morphologi-In order to probe the affinity and specificity of PU24FCl cal and functional changes and apoptosis and that these for Hsp90, we tested its ability to compete with GM for occur at similar doses in all tested tumor types. binding to Hsp90 from tumor cells and also from normal tissues and organs. We used a homogeneous fluorescence polarization assay that can measure real-time Results and Discussions interactions of cellular Hsp90 with the inhibitors. The apparent affinity of PU24FCl for tumor Hsp90 from sev-Design of the PU Class and Its Representative Lead Compound, PU24FCl eral cellular lysates was relatively similar (an average relative binding affinity [EC 50 ] value of the six measured The N-terminal region of Hsp90 possesses a distinctive ATP/ADP binding pocket that is conserved from bacteria transformed cell lines of 0.22 Ϯ 0.06 M was calculated; Figures 2A and 2B) . Although the agent bound tightly to mammals but is not present in other molecular chaperones [17] . When bound to the pocket, ATP and ADP to Hsp90 found in transformed cells (breast cancer cell lines MCF-7, MDA-MB-468, and SKBr3, chronic myeloid adopt a C-shaped conformation found in other members of the superfamily of proteins called GHKL ATPases leukemia cell line K562, and small cell lung cancers NCI-N417 and NCI-H69 are presented), its affinity for normal (G ϭ DNA gyrase B, H ϭ Hsp90, K ϭ histidine kinase, L ϭ MutL) but not observed in the high-affinity ATP/ cell-Hsp90 was at least 10-(brain, pancreas and lung) to 50-fold lower (heart, kidney, and liver). Interestingly, ADP binding sites [18] [19] [20] . Unlike protein kinases, which bind ATP/ADP with high affinity, Hsp90 binds these nu-PU24FCl's affinity for Hsp90 present in normal tissue was not only lower but also much more variable than cleotides with low affinity and has weak ATPase activity [21-23]. Thus, due to the unique structure of this pocket, for transformed cells (an average EC 50 value for the six measured organs of 8.8 Ϯ 7.6 M was calculated) (Fig-an Hsp90 ligand has a priori a high chance for being specific. ure 2B). We were also able to confirm the previously reported higher affinity of 17AAG for tumor Hsp90 [8] . We have previously defined the requirements for spe- . MutL ATPase activity was relatively insen-in SKBr3, and 59 Ϯ 7 and 37.5 Ϯ 14 nM in MDA-MB-468, respectively. We tested GM for binding to Hsp90 sitive to inhibition by these agents at concentrations as high as 5 mM. Previously, 17AAG has been reported to from brain and obtained an EC 50 of 850 Ϯ 40 nM (in concordance with the 400 nM reported for 17AAG [8] ). bind with nanomolar affinity to ADE2 SAICAR purine synthetase, an enzyme involved in purine metabolic pro-Our results do not corroborate the previous finding that tumor Hsp90 from Her2-overexpressing cells (i.e., cessing. The consequences of this effect are not completely understood, but it may be the cause of some SKBr3) confers a higher affinity for 17AAG than Hsp90 found in other cancer cells [8] . We also found 17AAG in vivo toxicities of the drug. PU24FCl did not inhibit ADE2 enzyme activity at concentrations as high as 1 mM to be actively and potently binding to tumor Hsp90 from the SCLC cell lines NCI-H69 (EC 50 of 15 Ϯ 
expressing K562 cells (Figure 3F) at concentrations of PU24FCl above the growth inhibitory IC 50 for this cell PU24FCl retained activity in Rb-defective cancer cells. In these cells, such as SCLC cell lines (i.e., NCI-H69, NCI-line. At such concentrations of RD, only a maximal 20% GPA induction was reported [35]. A tumor cell subset N417) and certain breast cancer cells, such as MDA-MB-468, 17AAG is almost 2 log less sensitive than in most
including all of those with defective Rb function (i.e., Figure 3D ). The appearance of mitotic nuclei dependent because the agent potently inhibits Hsp90 from these tumors (see above) and the phenomenon is in the Rb-defective breast cancer cell line MDA-MB-468 occurred below 5 M ( Figure 3F ), again in correlation not observed with PU24FCl.
MDA-MB-468, NCI-N417, and NCI-H69), was resistant other cell lines (D.S., unpublished results and [33]). The cause of lack of potency in these cells is not Hsp90 to induction of G1 block by PU24FCl and was blocked in mitosis (

Degradation of Hsp90 Client Proteins Involved with other anti-cancer effects of the agent in MDA-MB-468 (Figures 2C and 2D). in Cell Growth and Survival and Tumor-Specific Transformation Induction of Apoptosis
Cell cycle arrest by PU24FCl was followed by apoptosis. The effects of PU24FCl on growth were correlated with its effects on Hsp90 client proteins. These proteins (i.e., The degree of apoptosis was cell type dependent ( Figure  4A ) but, as observed in Figure 4B , occurred at agent Her2, cMet, Raf-1, Akt, ER, mutant AR, mutant p53, and Bcr-Abl) are thought to be involved in the dysregulated concentrations that produce all other Hsp90-related anti-cancer effects of PU24FCl. A significant increase growth potential and survival of tumor cells and to drive or contribute to transformation in many tumor types.
in the number of apoptotic nuclei was observed in Her2overexpressing (i.e., SKBr3; 19%) and Rb-defective (i.e., Their levels 24 hr after treatment were determined by Western blot ( Figure 2D ). Degradation of these Hsp90
MDA-MB-468 and NCI-N417; 44% and 35%, respectively) cells at 72 hr after treatment. client proteins occurred at similar concentrations in the panel of cancer cells tested, in concordance with the similar affinity of the drug for the chaperone in these
In Vivo Effects of PU24FCl-Accumulation of Drug in Tumors Leads tumor cells (Figure 2A and 
data not shown). A significant reduction was observed for most Hsp90 client proteins to Anti-Cancer-Effective Concentrations Pharmacokinetic Analysis as early as 8 hr after treatment, whereas no changes in PI3K (p85 unit) and ␤-actin, proteins not chaperoned by
The plasma concentration-time profile of PU24FCl after intraperitoneal (IP) and intravenous (IV) administration Hsp90, were observed (data not shown). Figures 5B and 5D) . In contrast to 17AAG administration, no induction of Hsp70 was observed in tumors at tissue with a maximum peak of 14.4 M recorded 24 hr after administration ( Figure 5B ). An AUC 6-48 hr of 221.6 the indicated times and doses (Figures 5C, 5D, and 5F ). This is a somewhat surprising observation when one M·min·ml Ϫ1 was observed for tumor tissue, suggesting that the in vitro effective dose of 10 M (IC 90 for most considers that, when it is administered in tissue culture to MCF-7 cells, PU24FCl does induce Hsp70 levels. It cancer cells) was maintained in tumors for approximately 10 hr (20-30 hr after administration). The AUC 6-48 hr is not clear what the significance of Hsp70 induction in tumors might be, but it has been suggested that in-values for blood and normal tissue were recorded as 0.98 M·min·ml Ϫ1 for serum, 8.9 M·min·ml Ϫ1 for liver, creased Hsp70 levels could interfere with the apoptotic potential of Hsp90 inhibitors [37] . Similar pharmacody-and 0.3 M·min·ml Ϫ1 for brain. The highest concentrations in these tissues were 0.06, 0.67, and 0.01 M, namic profile of PU24FCl was observed in mice bearing BT-474 breast cancer xenograft tumors, suggesting that respectively, with values declining sharply after 12 hr. These values suggest that in the interval of 6-48 hr after the in vivo effects of the agent may not be restricted to one tumor type and that wide-range targeting of onco-administration, PU24FCl is mostly distributed to tumors (226, 25, and 753 times more than in blood, liver, and genic transformation may also be achieved in vivo (Figure 5F) . Our results also suggest that the broad-range brain, respectively). They also hint to breakdown and clearance of the drug by the hepatic system after long-anti-tumor activity should occur at similar doses, in concordance with this drug's affinity for tumor Hsp90. The term presence in the body. The accumulation of PU24FCl in tumors is consistent with this agent's higher in vivo degradation of Hsp90 client proteins by PU24FCl may translate to the usefulness of this agent or more affinity for tumor versus normal tissue Hsp90 (Figure 2) .
Arrest of the Cell Cycle by PU24FCl Is Specific was determined. PU24FCl concentrations declined in an exponential fashion with a rapid absorption and dis-to Cell Type but Occurs at Similar Doses in All Transformed
Pharmacodynamic Analysis potent agents of this class in several malignancies. The transmembrane tyrosine kinases whose degradation is To probe the efficacy and safety of PU24FCl as an Hsp90 inhibitor in vivo, we used mice bearing MCF-7 breast
induced by PU24FCl include Her2, Her3, and Her4 (Figures 5C, 5D, and 5F) . Figure  4A ). As pharmacodynamic markers, we followed the ef-or to inhibit the activity of the kinases (i.e., Herceptin and Iressa). "Kinase-dead" receptors can still function fect of PU24FCl on Hsp90 client proteins, such as Akt 
The overexpression of these recep-cancer xenograft tumors. When compared to Her2-overexpressing breast cancer cell lines, MCF-7 shows only tors has been associated with aggressive malignancies [38] and several therapeutic strategies targeting the re-a modest response to 17AAG and is one of the cancer cell lines that evades apoptosis after Hsp90 inhibition ceptors are now in various stages of clinical development [39]. These strategies act to block the activation or other pharmacological interferences ([32, 36];
The high affinity of PU24FCl for tumor Hsp90 leads to accumulation in tumors with rapid clearance from normal tissue. (A and B) Pharmacokinetic analysis of PU24FCl. (A) Early distribution (0 to 4 hr): mean plasma concentrations of PU24FCl versus time after single IP and IV bolus administration of 70 mg/kg PU24FCl to mice. The agent's concentration in serum was monitored from 0 to 4 hr after administration and showed rapid adsorption and distribution. (B) Late distribution (6 to 48 hr): one dose of PU24FCl was administered intraperiotneally to MCF-7 (200 mg/kg) tumor-bearing mice for the indicated time periods. Mice were sacrificed, and tumors, organs, and serum were harvested. Drug distribution in tissue and serum was analyzed by LC-MS. In tumors, PU24FCl accumulated to concentrations found in vitro and induced all of its Hsp90-dependent anti-cancer effects while being rapidly cleared from organs. (C-F) Pharmacodynamic effects of PU24FCl. (C) The effect of PU24FCl on Hsp90 clients is dose dependent. PU24FCl was administered intraperitoneally or by PO to MCF
as a substrate for other receptors and non-receptor ki-
mality may be insufficient in reversing transformation and would be limited to use in a small subset of can-nases and thus act as a docking protein capable of signaling. Thus, a more significant therapeutic outcome cers. It has been suggested that one potential way to circumvent this problem is to target the machinery that may result from degrading these oncoproteins via Hsp90 inhibition [40] . We have shown Akt and Raf-1 to be addi-allows most cancer cells to function with the burden of abnormalities they carry: the chaperone Hsp90. We tional in vivo targets of PU24FCl (Figures 5C, 5D, and  5F) 
. ml penicillin, 50 units/ml streptomycin, and 5%-10% heat-inactivated fetal bovine serum (Gemini Bioproducts) and incubated at
Fixed monolayers were washed with distilled water and blocked with 5% BSA in PBS solution. After blocking took place, cells were 37ЊC, 5% CO 2 .
incubated with the primary antibody (anti-MFMG, Chemicon, 1:100 in 5% BSA in PBS) at 37ЊC and washed three times with 1% BSA Growth Assays in PBS; incubation with a rhodamine-labeled secondary antibody Growth inhibition studies were performed with the sulforhodamine followed for 1 hr at 37ЊC. B assay as previously described [16] . In summary, experimental Mitotic Block cultures were plated in microtiter plates (Nunc). One column of wells Harvested cells were washed in PBS, fixed in methanol for 20 min was left without cells to serve as the blank control. Cells were at Ϫ20ЊC, washed again in PBS, and blocked for 30 min in PBS allowed to attach overnight. The following day, growth medium havwith 5% BSA. Cells were stained first with mouse monoclonal antiing either drug or DMSO at twice the desired initial concentration ␣-tubulin (Sigma) and then with rhodamine-conjugated anti-mouse was added to the plate in triplicate and was serially diluted at a 1:1 antibody as well as 1 g/ml DAPI. Results were visualized, imaged, ratio in the microtiter plate. After 72 hr of growth, the cell number and quantified under confocal microscopy. in treated versus control wells was estimated after treatment with 10% trichloroacetic acid and staining with 0.4% sulforhodamine B in 1% acetic acid. The IC 50 was calculated as the drug concentration Animal Studies that inhibits cell growth by 50% compared with control growth.
Four-to 6-week-old nu/nu athymic female mice were obtained from Normal prostate epithelial cells (PrEC) and human renal proximal the National Cancer Institute-Frederick Cancer Center and maintubular epithelial (RPTEC) cells were purchased preseeded in 96tained in ventilated caging. Experiments were carried out under an well plates (Clonetics, CC-0088 and 3190, respectively). Upon re-Institutional Animal Care and Use Committee-approved protocol, ceipt, cells were placed in a humidified incubator at 37ЊC, 5% CO 2 and institutional guidelines for the proper and humane use of aniand allowed to equilibrate for 3 hr. Media were removed by suction mals in research were followed. MCF-7 (5 ϫ 10 6 cells) or BT-474 and replaced with fresh media provided by the manufacturer. Cells (1 ϫ 10 7 cells) human mammary tumor cells were subcutaneously were then treated with either drugs or DMSO for 72 hr, and the IC 50 implanted in the right flank of nu/nu athymic mice via a 20 gauge values were determined as described above.
needle and allowed to grow. Three days prior to tumor inoculation, 0.72 mg 17␤-estradiol 90-day release pellets (Innovative Research Protein Assays of America, Sarasota, FL) were implanted subcutaneously in the left Cells were grown to 60%-70% confluence and exposed to drugs or flank. For pharmacodynamic studies, tumors were allowed to reach DMSO vehicle for the indicated time periods. Lysates were prepared 6-8 mm in diameter before treatment. 20 l of supernatant was injected into the column. The PU24FCl peak appeared at 7.5 min. For growth studies, tumors were allowed Differentiation of K562 to reach 5 mm in diameter, and then animals were randomly divided Expression of the erythroid-specific surface marker GPA was deterinto the treatment groups (n ϭ 5). Mice were treated every other day mined by a previously described method [35] . In brief, 1 ϫ 10 6 cells with a dose of 200 mg/kg and then monitored for tumor progression. were incubated at 4ЊC for 30 min with 100 l (10 g/ml) of mouse Tumor dimensions were measured every 2 days with vernier caliantihuman GPA monoclonal antibody (Pharmingen). Next, cells were pers, and tumor volumes were calculated with the formula /6 ϫ washed twice with ice-cold PBS to remove unbound antibody, relarger diameter ϫ (smaller diameter) 2 . Mice with established tumors suspended in 10 g/ml of FITC-labeled goat anti-mouse IgG (Wako), of 4-5 mm in diameter were selected for study (n ϭ 5 per treatment and incubated at 4ЊC for 30 min in the dark. The cells were then group). While on therapy, all mice received Augmentin (Amoxicillin/ washed twice with ice-cold PBS and resuspended in 1% paraformal-Clavulanate potassium; SmithKline Beecham) in their drinking water. dehyde in PBS (pH 7.4). Mouse IgG1 (Wako) was used as an isotype-Mice were sacrificed by CO 2 euthanasia. matched negative control for each sample. 10 ϫ 10 3 events were analyzed for each sample by FACScan (Becton Dickinson).
